NDA Filings
The formal application asking the FDA to approve a new small-molecule drug — the milestone that starts the review clock toward a PDUFA date.
October 20261
November 20262
December 20267
January 20272
About NDA Filings
A New Drug Application (NDA) is the formal request a company files to ask the FDA to approve a new small-molecule (chemically synthesized) drug for marketing. It packages the full preclinical and clinical dataset, manufacturing details, and proposed labeling.
Filing is followed by an FDA “acceptance” decision (typically within 60 days), which sets the PDUFA goal date. The submission itself, its acceptance, and any Priority Review designation are each catalysts on the road to approval.
Why NDA Filings matter to investors
An NDA filing de-risks a program: it signals the company believes its Phase 3 package is approvable and starts the countdown to a decision. Acceptance with Priority Review shortens the timeline and is often read as a bullish tell about the strength of the data.
Frequently asked questions
What is an NDA filing?
A New Drug Application is the formal submission asking the FDA to approve a new small-molecule drug. Its acceptance sets the PDUFA date that governs the review.
What is the difference between an NDA and a BLA?
An NDA is for small-molecule (chemically synthesized) drugs; a BLA (Biologics License Application) is for biologics such as antibodies, vaccines and cell/gene therapies. Both follow the PDUFA review framework.
What happens after an NDA is filed?
The FDA decides within ~60 days whether to accept it for review and assigns a PDUFA target action date, optionally granting Priority Review to shorten the timeline.